The clinical trial arena has been hit by sweeping changes in the last few years.
During the pandemic, the acceleration of tech-enabled approaches such as decentralized clinical trials helped create a new paradigm for how patients could participate in research. The push for real-world data and more insights on patient outcomes has also helped give rise of new tech capabilities including wearable devices for remote monitoring, user-friendly apps to boost engagement and integrated platforms that make patients and trial operators more connected that ever before.
At the same time, persistent challenges hover over the space, such as the need to remove DEI barriers that hinder trial participation.
The clinical trial gurus included in this year’s PharmaVoice 100 are meeting this moment head on while helping their companies and the industry adopt the cutting edge technologies and strategies that will lead to more efficient, more diverse and better-informed drug research.
“We’ve come a long way in evolving the way we conduct research to embrace a patient’s preferences. But we still have much work ahead.” Read more ➔
“Understanding patient perspectives is crucial for developing effective solutions.” Read more ➔
“I try to create an environment that allows my team to feel safe, even if something doesn’t go to plan.” Read more ➔
“I am a big data person and believe that data is a fundamental part of making sound judgment decisions.” Read more ➔
“I believe the next wave of therapeutics, coupled with the technology enhancing clinical research, will transform how we study drugs and treat diseases.” Read more ➔
“There is a growing recognition that personalized medicine is within reach and that we must move to a model of preventing chronic disease.” Read more ➔
“We empower our teams and challenge them to never settle.” Read more ➔
“I’m energized by the diversity of thought the industry is welcoming to advance solutions on key persistent challenges.” Read more ➔
Dr. Xiao-Yu Song
“Being in the labs to see innovation in action is exhilarating. The notion of ‘what could happen if?’ is what drew me to science, and still fuels me today.” Read more ➔
“Talk less. Do more.” Read more ➔
Dr. Pam Tenaerts
“I’m motivated by the industry’s adoption of technologies and DCTs to improve patient experiences, access to trials and protocol performance.” Read more ➔